Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology

No‐Joon Song, Carter Allen, Anna E. Vilgelm, Brian Riesenberg, Kevin P. Weller, Kelsi Reynolds, Karthik B. Chakravarthy, Amrendra Kumar, Aastha Khatiwada, Zequn Sun, Anjun Ma, Yuzhou Chang, Mohamed Yusuf, Anqi Li, Cong Zeng, John P. Evans, Donna Bucci, Manuja Gunasena, Menglin Xu, Namal P. M. Liyanage, Chelsea Bolyard, Maria Velegraki, Shan‐Lu Liu, Qin Ma, Martin Devenport, Yang Liu, Pan Zheng, Carlos Malvestutto, Dongjun Chung, Zihai LiJournal of Hematology & Oncology 2022 · DOI

TL;DR

Researchers have found that CD24Fc—a soluble version of a natural immune "checkpoint"—acts as a powerful brake on the systemic inflammation (cytokine storm) seen in severe COVID-19. By analyzing patients from a Phase III clinical trial, the study shows that CD24Fc doesn't just block a single inflammatory signal; it reshapes the entire immune network, reducing the hyper-activation of T cells and NK cells while preserving the body's ability to produce anti-viral antibodies.

What Problem Does This Paper Address?

While vaccines are effective at preventing severe disease, treating patients who are already hospitalized with severe COVID-19 remains a challenge. The primary cause of death in these cases isn't usually the virus itself, but the body’s overzealous immune response—often called a "cytokine storm."

Current treatments like dexamethasone (a broad steroid) or IL-6 inhibitors (which block one specific signal) have limitations. There is a need for "broader-acting" immunomodulators that can target the root of the innate immune system's overreaction. This paper investigates CD24Fc, a fusion protein that mimics CD24, a molecule that normally tells the immune system to "calm down" after detecting tissue damage (DAMPs).

Methods

The authors used a "systems biology" approach to analyze blood samples from 22 patients enrolled in the SAC-COVID Phase III trial (randomized to receive either CD24Fc or a placebo).

Key techniques included:

  • High-Dimensional Spectral Flow Cytometry: Using 36-color and 25-color panels to identify 12 distinct immune cell clusters and track their activation states with extreme precision.
  • Principal Component Analysis (PCA) for "Activation Scores": Instead of looking at markers in isolation, they used PCA to combine multiple markers (like Ki-67, CD69, and GZMB) into a single, statistically robust "activation score" for different cell types.
  • Cytokine Network Analysis: They measured 30+ cytokines and chemokines and used eigenvector centrality—a graph theory metric—to determine how "connected" the inflammatory network was. A highly connected network indicates a runaway, co-regulated inflammatory response.

Datasets

  • Primary Dataset: Longitudinal blood samples from 22 COVID-19 patients (10 treated with CD24Fc, 12 with placebo) at The Ohio State University Wexner Medical Center.
  • Control Group: Samples from 17–25 healthy donors (HD).
  • Validation Dataset: A previously published external dataset (Lucas et al., 2020) comparing cytokine profiles of ICU vs. non-ICU COVID-19 patients to validate their network connectivity findings.

Key Insights and Ideas

  • The "Brake" Mechanism: CD24Fc works by binding to DAMPs (danger signals released by dying cells) and signaling through the Siglec10 pathway to blunt NF-κB activation. It essentially prevents the immune system from "tripping" over its own debris.
  • Normalization, Not Suppression: Unlike broad immunosuppressants, CD24Fc appeared to "normalize" the immune system. It reduced the hyper-activation of CD8+ T cells and NK cells back toward levels seen in healthy donors, but it did not compromise the patients' ability to produce antibodies against the SARS-CoV-2 Spike protein.
  • Network De-correlation: One of the most striking findings was that in severe COVID-19, cytokines become highly correlated (they all fire at once). CD24Fc "de-correlated" this network. The researchers showed that a less connected cytokine network is a hallmark of milder disease and successful recovery.
  • NK Cell Impact: While much focus is often on T cells, this study highlights that NK cells are severely dysregulated in COVID-19. CD24Fc was particularly effective at rapidly normalizing NK cell activation.

Key Results

  • Clinical Efficacy: In the parent Phase III trial, CD24Fc reduced the median time to clinical recovery from 10 days (placebo) to 6 days.
  • Cellular Changes: CD24Fc-treated patients showed a significant reduction in T cell and NK cell activation scores by Day 8 (p < 0.001).
  • Cytokine Reduction: Specifically, CD24Fc significantly down-modulated IL-10 and IL-15, two cytokines strongly linked to COVID-19 severity and mortality.
  • Network Connectivity: The "centrality" of the cytokine network—how much the signals reinforce each other—was significantly lower in the CD24Fc group compared to the placebo group, mirroring the profiles of non-ICU patients.

Limitations and Future Work

  • Sample Size: While the clinical trial was large, this specific deep-phenotyping sub-study only looked at 22 patients from a single center.
  • Mechanistic Depth: While the study shows that the network changes, the exact molecular crosstalk between the Siglec10 pathway and the specific cytokine clusters (like IL-15) in humans requires further mechanistic study.
  • Long-term Effects: The study focused on the acute 28-day recovery period; the impact of CD24Fc on "Long COVID" or long-term immune memory remains unknown.
  • Broader Application: The authors suggest this "network-based" analysis could be a blueprint for evaluating anti-inflammatory drugs in other conditions like autoimmune diseases or graft-versus-host disease (GVHD).

Summary updated

Abstract

Our data demonstrate that CD24Fc rapidly down-modulates systemic inflammation and restores immune homeostasis in SARS-CoV-2-infected individuals, supporting further development of CD24Fc as a novel therapeutic against severe COVID-19.
BibTeX
@article{song2022treatment,
  author = {No‐Joon Song and Carter Allen and Anna E. Vilgelm and Brian Riesenberg and Kevin P. Weller and Kelsi Reynolds and Karthik B. Chakravarthy and Amrendra Kumar and Aastha Khatiwada and Zequn Sun and Anjun Ma and Yuzhou Chang and Mohamed Yusuf and Anqi Li and Cong Zeng and John P. Evans and Donna Bucci and Manuja Gunasena and Menglin Xu and Namal P. M. Liyanage and Chelsea Bolyard and Maria Velegraki and Shan‐Lu Liu and Qin Ma and Martin Devenport and Yang Liu and Pan Zheng and Carlos Malvestutto and Dongjun Chung and Zihai Li},
  title = {{Treatment with soluble CD24 attenuates COVID-19-associated systemic immunopathology}},
  journal = {Journal of Hematology \& Oncology},
  year = {2022},
  doi = {10.1186/s13045-021-01222-y},
}
Figure